EGFR and idiopathic pulmonary fibrosis: Pathological activation of ERBB/Yes-Associated Protein (YAP) in IPF patients’ airway epithelium regulates epithelial-driven mesenchymal transition (Stancil et al., 2021), and EGFR-targeting drugs have a particular effect on alleviating the inflammatory and fibrotic process of IPF (Wang et al., 2022).